

If a conflict arises between a Clinical Payment and Coding Policy (“CPCP”) and any plan document under which a member is entitled to Covered Services, the plan document will govern. If a conflict arises between a CPCP and any provider contract pursuant to which a provider participates in and/or provides Covered Services to eligible member(s) and/or plans, the provider contract will govern. “Plan documents” include, but are not limited to, Certificates of Health Care Benefits, benefit booklets, Summary Plan Descriptions, and other coverage documents. BCBSIL may use reasonable discretion interpreting and applying this policy to services being delivered in a particular case. BCBSIL has full and final discretionary authority for their interpretation and application to the extent provided under any applicable plan documents.

Providers are responsible for submission of accurate documentation of services performed. Providers are expected to submit claims for services rendered using valid code combinations from Health Insurance Portability and Accountability Act (“HIPAA”) approved code sets. Claims should be coded appropriately according to industry standard coding guidelines including, but not limited to: Uniform Billing (“UB”) Editor, American Medical Association (“AMA”), Current Procedural Terminology (“CPT®”), CPT® Assistant, Healthcare Common Procedure Coding System (“HCPCS”), ICD-10 CM and PCS, National Drug Codes (“NDC”), Diagnosis Related Group (“DRG”) guidelines, Centers for Medicare and Medicaid Services (“CMS”) National Correct Coding Initiative (“NCCI”) Policy Manual, CCI table edits and other CMS guidelines.

Claims are subject to the code edit protocols for services/procedures billed. Claim submissions are subject to claim review including but not limited to, any terms of benefit coverage, provider contract language, medical policies, clinical payment and coding policies as well as coding software logic. Upon request, the provider is urged to submit any additional documentation.

Testing for Homocysteine Metabolism-Related Conditions

Policy Number: CPCPLAB067

Version 1.0

Enterprise Medical Policy Committee Approval Date: January 25, 2022

Plan Effective Date: May 1, 2022

Description

BCBSIL has implemented certain lab management reimbursement criteria. Not all requirements apply to each product. Providers are urged to review Plan documents for eligible coverage for services rendered.

Reimbursement Information:

1. Newborn screening for homocysteine-related conditions **may be reimbursable** in the following situations:
 - a. For classic homocystinuria due to CBS deficiency by performing quantitative plasma amino acids analysis and/or plasma or urine total homocysteine analysis.
 - b. Testing for homocystinuria in dried blood spots.
 - c. Testing for hypermethioninemia in dried blood spots.

2. A repeat dried blood specimen submitted to the newborn screening program, or a quantitative plasma amino acid analysis and analysis of plasma total homocysteine **may be reimbursable** if the initial screening test result exceeds the cut-off level of methionine.
3. Pyridoxine (B6) Challenge test **may be reimbursable** to diagnose phenotype variants of classic homocystinuria due to cystathionine β -synthase (CBS) deficiency.
4. Total homocysteine testing in plasma **may be reimbursable** in patients over 18 years with suspected CBS deficiency with homocystinuria and for monitoring therapy in those with confirmed CBS.
5. Plasma free homocysteine testing **is not reimbursable**

Procedure Codes

Codes
82136, 82139, 82615, 83090, 83921, 84207

References:

Abbott, M. H., Folstein, S. E., Abbey, H., & Pyeritz, R. E. (1987). Psychiatric manifestations of homocystinuria due to cystathionine beta-synthase deficiency: prevalence, natural history, and relationship to neurologic impairment and vitamin B6-responsiveness. *Am J Med Genet*, 26(4), 959-969. doi:10.1002/ajmg.1320260427

ACMG. (2009). Methionine Elevated or Decreased. Retrieved from <http://www.acmg.net/PDFLibrary/Methionine-Algorithm.pdf>

ACMG. (2010). Newborn Screening ACT Sheet [Increased Methionine] Homocystinuria (CBS Deficiency) Retrieved from <http://www.acmg.net/PDFLibrary/Homocystinuria>

Al-Sadeq, D. W., & Nasrallah, G. K. (2020). The Spectrum of Mutations of Homocystinuria in the MENA Region. *Genes (Basel)*, 11(3). doi:10.3390/genes11030330

Belkhiria, M. N., Ducros, V., Harzallah, K., Jarraya, F., Cordonnier, D., Favier, A., & Achour, A. (2007). [Evaluation of plasmatic homocysteine determination by gas chromatography-mass spectrometry]. *Ann Biol Clin (Paris)*, 65(4), 393-398.

Collison, F. T., Xie, Y. A., Gambin, T., Jhangiani, S., Muzny, D., Gibbs, R., . . . Allikmets, R. (2015). Whole Exome Sequencing Identifies an Adult-Onset Case of Methylmalonic Aciduria and Homocystinuria Type C (cb1C) with Non-Syndromic Bull's Eye Maculopathy. *Ophthalmic Genet*, 36(3), 270-275. doi:10.3109/13816810.2015.1010736

Concepción-Alvarez, A., Camayd-Viera, I., & Nuevas-Paz, L. (2016). Validation of an HPLC method for total homocysteine quantification in plasma. *Revista del Laboratorio Clinico*, 9(2), 40-47. Retrieved from <https://www.sciencedirect.com/science/article/pii/S1888400816300022#!>

de Sain-van der Velden, M. G. M., van der Ham, M., Jans, J. J., Visser, G., van Hasselt, P. M., Prinsen, H., & Verhoeven-Duif, N. M. (2015). Suitability of methylmalonic acid and total homocysteine analysis in dried bloodspots. *Anal Chim Acta*, 853, 435-441. doi:10.1016/j.aca.2014.10.043

FDA. (2020). Devices@FDA. Retrieved from <https://www.accessdata.fda.gov/scripts/cdrh/devicesatfda/index.cfm>

Froese, D. S., Kopec, J., Fitzpatrick, F., Schuller, M., McCorvie, T. J., Chalk, R., . . . Yue, W. W. (2015). Structural Insights into the MMACHC-MMADHC Protein Complex Involved in Vitamin B12 Trafficking. *J Biol Chem*, 290(49), 29167-29177. doi:10.1074/jbc.M115.683268

Gaughan, D. J., Kluijtmans, L. A., Barbaux, S., McMaster, D., Young, I. S., Yarnell, J. W., . . . Whitehead, A. S. (2001). The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations. *Atherosclerosis*, 157(2), 451-456.

Gaustadnes, M., Ingerslev, J., & Rütiger, N. (1999). Prevalence of Congenital Homocystinuria in Denmark. *New England Journal of Medicine*, 340(19), 1513-1513. doi:10.1056/NEJM199905133401915

Harmon, D. L., Shields, D. C., Woodside, J. V., McMaster, D., Yarnell, J. W., Young, I. S., . . . Whitehead, A. S. (1999). Methionine synthase D919G polymorphism is a significant but modest determinant of circulating homocysteine concentrations. *Genet Epidemiol*, 17(4), 298-309. doi:10.1002/(sici)1098-2272(199911)17:4<298:Aid-gepi5>3.0.Co;2-v

HHS. (2018, 02/2019). Recommended Uniform Screening Panel. Retrieved from <https://www.hrsa.gov/advisory-committees/heritable-disorders/rusp/index.html>

Huemer, M., Kožich, V., Rinaldo, P., Baumgartner, M. R., Merinero, B., Pasquini, E., . . . Blom, H. J. (2015). Newborn screening for homocystinurias and methylation disorders: systematic review and proposed guidelines. *Journal of inherited metabolic disease*, 38(6), 1007-1019. doi:10.1007/s10545-015-9830-z

Ismayilova, N., MacKinnon, A. D., Mundy, H., & Fallon, P. (2019). Reversible Cerebral White Matter Abnormalities in Homocystinuria. *JIMD Rep*, 44, 115-119. doi:10.1007/8904_2018_135

Janosík, M., Sokolová, J., Janosíková, B., Krijt, J., Klatovská, V., & Kozich, V. (2009). Birth prevalence of homocystinuria in Central Europe: frequency and pathogenicity of mutation c.1105C>T (p.R369C) in the cystathionine beta-synthase gene. *The Journal of pediatrics*, 154(3), 431-437. doi:10.1016/j.jpeds.2008.09.015

Li, Barshop, Feigenbaum, & Khanna. (2018). Brain Magnetic Resonance Imaging Findings in Poorly Controlled Homocystinuria. *J Radiol Case Rep*. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/29875981>

Mazaheri, Mostofizadeh, & Hashemipour. (2017). Homocystinuria with Stroke and Positive Familial History. *Adv Biomed Res*. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/29279830>

Morris, A. A. M., Kožich, V., Santra, S., Andria, G., Ben-Omran, T. I. M., Chakrapani, A. B., . . . Chapman, K. A. J. J. o. I. M. D. (2017). Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency. 40(1), 49-74. doi:10.1007/s10545-016-9979-0

Mudd, S. H., Finkelstein, J. D., Refsum, H., Ueland, P. M., Malinow, M. R., Lentz, S. R., . . . Rosenberg, I. H. (2000). Homocysteine and its disulfide derivatives: a suggested consensus terminology. *Arterioscler Thromb Vasc Biol*, 20(7), 1704-1706.

Mudd, S. H., Skovby, F., Levy, H. L., Pettigrew, K. D., Wilcken, B., Pyeritz, R. E., . . . et al. (1985). The natural history of homocystinuria due to cystathionine beta-synthase deficiency. *Am J Hum Genet*, 37(1), 1-31.

Nelson, B. C., Pfeiffer, C. M., Sniegowski, L. T., & Satterfield, M. B. (2003). Development and evaluation of an isotope dilution LC/MS method for the determination of total homocysteine in human plasma. *Anal Chem*, 75(4), 775-784.

Nexo, E., Engbaek, F., Ueland, P. M., Westby, C., O'Gorman, P., Johnston, C., . . . Refsum, H. (2000). Evaluation of Novel Assays in Clinical Chemistry: Quantification of Plasma Total Homocysteine. *Clinical Chemistry*, 46(8), 1150. Retrieved from <http://clinchem.aaccjnl.org/content/46/8/1150.abstract>

NIH. (2018b). Homocystinuria due to CBS deficiency. Retrieved from <https://rarediseases.info.nih.gov/diseases/6667/homocystinuria-due-to-cbs-deficiency>

Okun, J. G., Gan-Schreier, H., Ben-Omran, T., Schmidt, K. V., Fang-Hoffmann, J., Gramer, G., . . . Hoffmann, G. F. (2017). Newborn Screening for Vitamin B6 Non-responsive Classical Homocystinuria: Systematical Evaluation of a Two-Tier Strategy. *JIMD Rep*, 32, 87-94. doi:10.1007/8904_2016_556

Rose, N. C., & Dolan, S. M. (2012). Newborn screening and the obstetrician. *Obstetrics and gynecology*, 120(4), 908-917. doi:10.1097/AOG.0b013e31826b2f03

Rosenson, R. S., Smith, C. C., & Bauer, K. A. (2020, October 26). Overview of homocysteine. Retrieved from <https://www.uptodate.com/contents/overview-of-homocysteine>

Sacharow, S. J., Picker, J. D., & Levy, H. L. (2004). Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency. In M. P. Adam, H. H. Ardinger, R. A. Pagon, S. E. Wallace, L. J. H. Bean, K. Stephens, & A. Amemiya (Eds.), *GeneReviews*((R)). Seattle (WA): University of Washington, Seattle University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.

Zhu, H., Blake, S., Chan, K. T., Pearson, R. B., & Kang, J. (2018). Cystathionine beta-Synthase in Physiology and Cancer. *Biomed Res Int*, 2018, 3205125. doi:10.1155/2018/3205125

Policy Update History:

5/1/2022	New policy
----------	------------